» Articles » PMID: 34082811

The Effect of Metabolic Syndrome on Head and Neck Cancer Incidence Risk: a Population-based Prospective Cohort Study

Overview
Journal Cancer Metab
Publisher Biomed Central
Specialty Oncology
Date 2021 Jun 4
PMID 34082811
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There are limited evidences clarifying the impact of metabolic syndrome (MS) and its components on head and neck cancer (HNC) incidence risk. We explored the correlation between MS, MS components, and the combined effects of MS and C-reactive protein (CRP) and HNC risk.

Methods: This is a prospective analysis of 474,929 participants from the UK Biobank cohort. Cox proportional hazard regression was utilized to assess the hazard ratio (HR) and 95% confidence interval (CI) and to explore the non-linear correlation between an individual MS component and HNC risk.

Results: Individuals with MS (HR, 1.05; 95%CI, 0.90-1.22) had no higher HNC risk than those without MS. More MS components showed no higher HNC risk. Nevertheless, hyperglycemia (HR, 1.22; 95%CI, 1.02-1.45) was independently correlated with elevated HNC risk. In a non-linear manner, waist circumference and high-density lipoprotein cholesterol (HDL-C) showed a U-shaped association with HNC risk. Further, piecewise linear model analysis indicated that higher male waist circumference, female waist circumference (≥93.16 cm), blood glucose (≥4.70 mmol/L) and male HDL-C (≥1.26mmo/L), and lower male HDL-C (<1.26mmo/L) were correlated with higher HNC risk. Increased CRP (≥1.00mg/dL) elevated HNC risk and individuals with MS and CRP≥1.00mg/dL had the highest HNC risk (HR, 1.29; 95%CI, 1.05-1.58). But no joint effect between MS and CRP was detected (p-interaction=0.501).

Conclusions: MS are not correlated with elevated HNC risk. High waist circumference and blood glucose are independent risk factor of HNC incidence. Controlling HDL-C in an appropriate range can get the lowest risk of male HNC. No joint effect of MS and CRP exists in HNC tumorigenesis.

Citing Articles

Impact of statin use in head and neck cancer: a nested case-control study.

Rhi H, Choi H, Kang J Eur Arch Otorhinolaryngol. 2024; 282(3):1443-1457.

PMID: 39441362 DOI: 10.1007/s00405-024-09020-1.


Lipid metabolism reprogramming in head and neck cancer.

Liang J, Li L, Li L, Zhou X, Zhang Z, Huang Y Front Oncol. 2023; 13:1271505.

PMID: 37927468 PMC: 10622980. DOI: 10.3389/fonc.2023.1271505.


Association between Metabolic Syndrome and Risk of Hypopharyngeal Cancer: A Nationwide Cohort Study from Korea.

Kang J, Cheong H, Kim S, Lee M, Lee Y, Oh I Cancers (Basel). 2023; 15(18).

PMID: 37760423 PMC: 10526337. DOI: 10.3390/cancers15184454.


Evaluating the effect of metabolic traits on oral and oropharyngeal cancer risk using Mendelian randomization.

Gormley M, Dudding T, Thomas S, Tyrrell J, Ness A, Pring M Elife. 2023; 12.

PMID: 37042641 PMC: 10147379. DOI: 10.7554/eLife.82674.


Relationship between Chronic Rhinosinusitis and the Incidence of Head and Neck Cancer: A National Population-Based Study.

Han K, Park S, Son S, Kim S, Kim I, Kim J J Clin Med. 2022; 11(18).

PMID: 36142963 PMC: 9506370. DOI: 10.3390/jcm11185316.


References
1.
Pais R, Silaghi H, Silaghi A, Rusu M, Dumitrascu D . Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol. 2009; 15(41):5141-8. PMC: 2773892. DOI: 10.3748/wjg.15.5141. View

2.
Keene D, Price C, Shun-Shin M, Francis D . Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014; 349:g4379. PMC: 4103514. DOI: 10.1136/bmj.g4379. View

3.
Lv Y, Miao L, Chen Q, Li Y, Shi Z, Ding X . Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma. Onco Targets Ther. 2016; 9:461-8. PMC: 4730999. DOI: 10.2147/OTT.S96199. View

4.
Murtola T, Kasurinen T, Talala K, Taari K, Tammela T, Auvinen A . Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Dis. 2018; 22(1):66-76. DOI: 10.1038/s41391-018-0087-0. View

5.
Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View